<SEC-DOCUMENT>0001004878-18-000014.txt : 20180119
<SEC-HEADER>0001004878-18-000014.hdr.sgml : 20180119
<ACCEPTANCE-DATETIME>20180118194310
ACCESSION NUMBER:		0001004878-18-000014
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20180119
DATE AS OF CHANGE:		20180118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CEL SCI CORP
		CENTRAL INDEX KEY:			0000725363
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				840916344
		STATE OF INCORPORATION:			CO
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-196243
		FILM NUMBER:		18535181

	BUSINESS ADDRESS:	
		STREET 1:		8229 BOONE BLVD .
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182
		BUSINESS PHONE:		7035069460

	MAIL ADDRESS:	
		STREET 1:		8229 BOONE BLVD.
		STREET 2:		SUITE 802
		CITY:			VIENNA
		STATE:			VA
		ZIP:			22182

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERLEUKIN 2 INC
		DATE OF NAME CHANGE:	19880317
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>prosupp196243jan-18.txt
<DESCRIPTION>PROSUPP S WARRANTS 196243
<TEXT>



PROSPECTUS SUPPLEMENT                           Filed pursuant to Rule 424(b)(3)
(To Prospectus Supplement dated                      Registration No. 333-196243
    October 21, 2014)


                               CEL-SCI CORPORATION
                                Series S Warrants



     On January 12, 2018 the exercise price of the Company's  outstanding Series
S warrants (CUSIP number  150837177),  that are publicly traded under the symbol
"CVM WS" on the NYSE American,  was changed to $3.00 per share for a three month
period which will end on April 12,  2018.  After this date,  the exercise  price
will revert back to $31.25 per share of common stock. As a result of the reverse
stock split which  became  effective on the NYSE  American on June 15, 2017,  25
Series S warrants are required to purchase one share of common stock. The Series
S warrants expire on October 11, 2018.





























                  Prospectus Supplement dated January 16, 2018


</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
